C57BL/6, B6.RAG1−/−Tyrp1B-w TRP-1 TCR transgenic, and B6.OPG−/− mice were purchased from The Jackson Laboratory. Mice were treated intraperitoneally with 100 µg anti-RANKL (IK22/5) or isotype control (2A3; Bio X Cell) antibody three times per week as stated in the text. B6.OT-II, B6.RIP-mOVA, and B6.IRBP−/− mice were described previously (Anderson et al., 2005 (link); DeVoss et al., 2006 (link)). Mice were treated at 3–5 wk of age and harvested at time points indicated in the text. All mice were housed and bred in specific pathogen-free conditions in animal facilities at UCSF or UNC, Chapel Hill. Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at UCSF or UNC, Chapel Hill.